
News|Articles|October 12, 2012
FDA approves therapy for first-line treatment of advanced NSCLC
FDA has approved paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (Abraxane, Celgene) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Myqorzo is now available for rare heart condition at a $108,400 annual price
2
PBM reform. It has finally happened
3
Study of antibody-Keytruda combination seeds hope for overcoming immune checkpoint inhibitor resistance, use of biomarkers
4
Melanoma diagnoses projected to rise in 2026
5























